Due to increased study into the genome's epigenetics (which is additionally referred to as epigenomics), the epigenetics market is predicted to grow more quickly than average over the coming years. Genome-wide epigenetic research is crucial for diagnosing human disorders. Additionally, it is anticipated that the use of epigenetics in oncology research will fuel the market's expansion. For instance, Constellation Pharmaceuticals committed US$ 100 million in April 2018 to the development of a cancer epigenetics platform and to the ongoing ProSTAR and ORIOn-E trials, which aim to show the efficacy of the cancer therapies CPI-1205 and CPI-0610. Additionally, the increase of whole genome sequencing initiatives like the Human Genome Project is leading to a rise in the consumption of products based on epigenetics, which in turn is propelling the expansion of the epigenetics market. The epigenetics industry is expanding as a result of rising government initiatives to advance epigenetic research. Epigenetics market companies are anticipated to use both organic and inorganic growth tactics, such as merger, cooperation, acquisition, and product launches, to drive market expansion.
According to Coherent Market Insights, The size of the global Epigenetics Market exceeded USD 1.9 billion in 2022, and it is anticipated to reach USD 6.35 billion by 2032. From 2023 to 2032, the market is projected to increase at a CAGR of 12.82%.
Leading Companies in the Epigenetics Industry:
Bio-Rad Laboratories Inc.
The firm was founded in 1952 and is based in California, United States. The business produces and sells analytical instruments, clinical diagnostics, and equipment for use in life science research. Products and systems from Bio-Rad Laboratories are used to separate complicated chemical and biological materials as well as to recognise, examine, and purify their constituent parts. In March 2021, Bio-Rad and Roche announced a partnership.
Thermo Fisher Scientific
The business was started in 1956 and has its headquarters in Waltham, Massachusetts, United States. Thermo Fisher Scientific, Inc. produces chemicals, consumables, and scientific equipment. The acquisition of PPD, Inc. by Thermo Fisher Scientific was announced in April 2021. Thermo Fisher Scientific said in January 2021 that it had purchased Henogen SA, a producer of viral vectors based in Belgium, from Groupe Novasep SAS for €725 million in cash.
